Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Yesterday, June 1, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $181.50 to $4,800,000.00. Highlighted Stocks Traded by Insiders: BioSpecifics Technologies (BSTC) - FREE Research Report Gitman Paul, who is Director at BioSpecifics Technologies, sold 15,000 shares at $46.76 on June 1, 2015. Following this transaction, the Director owned 51,825 shares meaning that the stake was reduced by 22.45% with the 15,000-share transaction. The shares most recently traded at $47.49, up $0.73, or 1.54% since the insider transaction. Historical insider transactions for BioSpecifics Technologies go as follows:
4-Week # shares sold: 2,950
12-Week # shares sold: 2,950
24-Week # shares sold: 2,950
The average volume for BioSpecifics Technologies has been 34,500 shares per day over the past 30 days. BioSpecifics Technologies has a market cap of $321.1 million and is part of the health care sector and drugs industry. Shares are up 23.36% year-to-date as of the close of trading on Monday. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has a P/E ratio of 54.8. Currently, there are no analysts who rate BioSpecifics Technologies a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on BSTC - FREETheStreet Quant Ratings rates BioSpecifics Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full BioSpecifics Technologies Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.